

Stephen M Stahl

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5523834/stephen-m-stahl-publications-by-year.pdf>

Version: 2022-09-30

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

195
papers

4,889
citations

40
h-index

67
g-index

233
ext. papers

6,228
ext. citations

3.6
avg, IF

6.43
L-index

#	Paper	IF	Citations
196	The effect of first- and second-generation antipsychotics on brain morphology in schizophrenia: A systematic review of longitudinal magnetic resonance studies with a randomized allocation to treatment arms.. <i>Journal of Psychopharmacology</i> , 2022 , 2698811221087645	4.4	
195	Mental energy: plausible neurological mechanisms and emerging research on the effects of natural dietary compounds. <i>Nutritional Neuroscience</i> , 2021 , 24, 850-864	3.4	1
194	Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action. <i>CNS Spectrums</i> , 2021 , 26, 232-242	1.7	1
193	REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study. <i>Frontiers in Pharmacology</i> , 2021 , 12, 671859	5.3	2
192	Response to the Letter to the Editor "Psychiatry's undeclared identity crisis in a changing world" by Richard Skaff. <i>CNS Spectrums</i> , 2021 , 1-2	1.7	
191	Precision and personalized assessment, diagnosis and treatment in psychiatry. <i>CNS Spectrums</i> , 2021 , 26, 326-332	1.7	2
190	How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice. <i>Acta Psychiatrica Scandinavica</i> , 2021 , 143, 172-180	6.2	2
189	REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.. <i>American Journal of Psychiatry</i> , 2021 , appiajp202121020197	11.3	3
188	Psychopharmacology and ethnicity: A comparative study on Senegalese and Italian men. <i>World Journal of Biological Psychiatry</i> , 2020 , 21, 300-307	3.6	1
187	Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies. <i>CNS Spectrums</i> , 2020 , 25, 502-510	1.7	82
186	New Medications for Neuropsychiatric Disorders. <i>Psychiatric Clinics of North America</i> , 2020 , 43, 399-413	2.9	1
185	Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data. <i>Therapeutic Advances in Psychopharmacology</i> , 2020 , 10, 2045125320905752	4.7	82
184	Pharmacologic Treatment of Mixed States. <i>Psychiatric Clinics of North America</i> , 2020 , 43, 167-186	2.9	2
183	Dementia-related psychosis and the potential role for pimavanserin. <i>CNS Spectrums</i> , 2020 , 1-9	1.7	2
182	Imipramine 2020 , 367-374		
181	Molindone 2020 , 527-532		
180	Diphenhydramine 2020 , 235-238		

179 Acamprosate **2020**, 1-4

178 Atomoxetine **2020**, 79-84

177 Flunitrazepam **2020**, 297-300

176 Lumateperone **2020**, 451-456

175 Galantamine **2020**, 337-342

174 Flumazenil **2020**, 293-296

173 Flupenthixol **2020**, 307-312

172 Asenapine **2020**, 71-78

171 Lofepramine **2020**, 421-426

170 Armodafinil **2020**, 65-70

169 Brexanolone **2020**, 99-102

168 Chlordiazepoxide **2020**, 147-152

167 Lurasidone **2020**, 457-464

166 Deutetrabenazine **2020**, 221-224

165 Nefazodone **2020**, 545-550

164 Dothiepin **2020**, 249-254

163 Mianserin **2020**, 495-498

162 Moclobemide **2020**, 515-520

161 Buspirone **2020**, 123-126

160 Oxazepam **2020**, 569-574

159 Desvenlafaxine **2020**, 215-220

158 Desipramine **2020**, 207-214

157 Isocarboxazid **2020**, 375-382

156 Nalmefene **2020**, 533-536

155 Dextromethorphan **2020**, 225-228

154 Clonazepam **2020**, 173-178

153 Methylphenidate (D,L) **2020**, 487-494

152 Naltrexone **2020**, 537-540

151 Levomilnacipran **2020**, 403-408

150 loperidone **2020**, 359-366

149 Nortriptyline **2020**, 551-558

148 Blonanserin **2020**, 89-94

147 Maprotiline **2020**, 465-472

146 Amphetamine (D,L) **2020**, 45-52

145 Doxepin **2020**, 255-262

144 Methylphenidate (D) **2020**, 481-486

143 Guanfacine **2020**, 343-346

142 Methylfolate (L) **2020**, 477-480

141 Hydroxyzine **2020**, 355-358

140 Esketamine **2020**, 275-280

139 Cariprazine **2020**, 137-146

1

138 Alprazolam **2020**, 11-16

137 Estazolam **2020**, 281-284

136 Flurazepam **2020**, 321-324

135 Cyamemazine **2020**, 201-206

134 Amphetamine (D) **2020**, 39-44

133 Amitriptyline **2020**, 25-32

132 Caprylidene **2020**, 127-130

131 Eszopiclone **2020**, 285-288

130 Bremelanotide **2020**, 95-98

129 Milnacipran **2020**, 503-508

128 Flibanserin **2020**, 289-292

127 Loxapine **2020**, 443-450

126 Fluphenazine **2020**, 313-320

125	Clomipramine 2020 , 165-172		
124	Fluvoxamine 2020 , 325-330		
123	Modafinil 2020 , 521-526		
122	Amisulpride 2020 , 17-24		
121	Benztropine 2020 , 85-88		
120	Lofexidine 2020 , 427-430		
119	Loflazepate 2020 , 431-436		
118	Prescriber's Guide 2020 ,		4
117	Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity. <i>CNS Spectrums</i> , 2019 , 24, 461-466	1.7	8
116	Mixed mood states: Baffled, bewildered, befuddled and bemused. <i>Bipolar Disorders</i> , 2019 , 21, 560-561	3.7	5
115	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. <i>CNS Spectrums</i> , 2019 , 24, 154-162	1.7	9
114	Conditions of life and death of psychiatric patients in France during World War II: euthanasia or collateral casualties?. <i>CNS Spectrums</i> , 2018 , 23, 170-175	1.7	1
113	Serotonin and Love: Supporting Evidence From a Patient Suffering From Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2018 , 38, 99-101	1.6	4
112	Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. <i>CNS Spectrums</i> , 2018 , 23, 402-413	1.7	3
111	Mixed-up about how to diagnose and treat mixed features in major depressive episodes. <i>CNS Spectrums</i> , 2017 , 22, 111-115	1.7	10
110	Guidelines for the recognition and management of mixed depression. <i>CNS Spectrums</i> , 2017 , 22, 203-219	1.7	70
109	Flibanserin - the female Viagra?. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017 , 21, 259-265	2.3	1
108	Drug information update. Unconventional treatment strategies for schizophrenia: polypharmacy and heroic dosing. <i>BJPsych Bulletin</i> , 2017 , 41, 164-168	1.2	4

107	Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 114-128	6.2	95
106	Inverse agonists - What do they mean for psychiatry?. <i>European Neuropsychopharmacology</i> , 2017 , 27, 87-90	0.8	10
105	Does a "whiff" of mania in a major depressive episode shift treatment from a classical antidepressant to an atypical/second-generation antipsychotic?. <i>Bipolar Disorders</i> , 2017 , 19, 595-596	3.7	2
104	Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction. <i>Case Reports in Psychiatry</i> , 2016 , 2016, 5606098	0.6	7
103	Psychopharmacology of Persistent Violence and Aggression. <i>Psychiatric Clinics of North America</i> , 2016 , 39, 541-556	2.9	13
102	Major Depressive Disorder: Understanding the Significance of Residual Symptoms and Balancing Efficacy with Tolerability. <i>American Journal of Medicine</i> , 2015 , 128, S1-S15	2.3	44
101	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. <i>European Neuropsychopharmacology</i> , 2015 , 25, 2318-25	0.8	83
100	Psychopharmacology: Child and Adolescent 2015 , 1-14		
99	Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy. <i>CNS Spectrums</i> , 2014 , 19, 439-48	1.7	23
98	A proposal for an updated neuropsychopharmacological nomenclature. <i>European Neuropsychopharmacology</i> , 2014 , 24, 1005-14	0.8	57
97	Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. <i>CNS Spectrums</i> , 2014 , 19, 207-12	1.7	92
96	Pharmacotherapy of cognitive deficits in schizophrenia. <i>CNS Spectrums</i> , 2014 , 19, 142-56	1.7	15
95	Genetics and Epigenetics of Mental Illness: Implications for Diagnosis and Treatment 2014 , 1-9		
94	Long-acting injectable antipsychotics: shall the last be first?. <i>CNS Spectrums</i> , 2014 , 19, 3-5	1.7	47
93	California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. <i>CNS Spectrums</i> , 2014 , 19, 449-465	1.7	23
92	Modulating the serotonin system in the treatment of major depressive disorder. <i>CNS Spectrums</i> , 2014 , 19 Suppl 1, 57-67; quiz 54-7, 68	1.7	29
91	Emerging guidelines for the use of antipsychotic polypharmacy. <i>Revista De Psiquiatria Y Salud Mental (English Edition)</i> , 2013 , 6, 97-100	0.2	1
90	Meta-guidelines for the management of patients with schizophrenia. <i>CNS Spectrums</i> , 2013 , 18, 150-162	1.7	45

89	The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities?. <i>Trends in Pharmacological Sciences</i> , 2013 , 34, 332-9	12.7	141
88	The last Diagnostic and Statistical Manual (DSM): replacing our symptom-based diagnoses with a brain circuit-based classification of mental illnesses. <i>CNS Spectrums</i> , 2013 , 18, 65-8	1.7	20
87	Off-label prescribing: best practice or malpractice?. <i>CNS Spectrums</i> , 2013 , 18, 1-4	1.7	8
86	Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. <i>Journal of Clinical Psychiatry</i> , 2013 , 74, 507-15	4.4	42
85	Serotonergic drugs for depression and beyond. <i>Current Drug Targets</i> , 2013 , 14, 578-85	2.8	142
84	Should High Dose or Very Long-Term Antipsychotic Monotherapy Be Considered Before Antipsychotic Polypharmacy? 2013 , 107-125		
83	Drug research: a plan for mental illness. <i>Nature</i> , 2012 , 483, 269	47.1	53
82	A horse of a different color: how formulation influences medication effects. <i>CNS Spectrums</i> , 2012 , 17, 63-9	1.7	1
81	Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment. <i>CNS Spectrums</i> , 2012 , 17 Suppl 1, 10-21	1.7	8
80	Ziprasidone hydrochloride: what role in the management of schizophrenia?. <i>Journal of Central Nervous System Disease</i> , 2011 , 3, 1-16	4.2	9
79	Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder. <i>Journal of Sexual Medicine</i> , 2011 , 8, 15-27	1	156
78	Treatment strategies for dosing the second generation antipsychotics. <i>CNS Neuroscience and Therapeutics</i> , 2011 , 17, 110-7	6.6	20
77	Ziprasidone in the Treatment of Bipolar Disorder 2011 , 223-244		
76	Case Studies: Stahl's Essential Psychopharmacology 2011 ,		11
75	How to dose a psychotropic drug: beyond therapeutic drug monitoring to genotyping the patient. <i>Acta Psychiatrica Scandinavica</i> , 2010 , 122, 440-1	6.2	78
74	Fooling mother nature: epigenetics and novel treatments for psychiatric disorders. <i>CNS Spectrums</i> , 2010 , 15, 358-65	1.7	10
73	Psychiatric stress testing: novel strategy for translational psychopharmacology. <i>Neuropsychopharmacology</i> , 2010 , 35, 1413-4	8.3	12
72	Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Psychopharmacology</i> , 2010 , 30, 135-44	1.6	75

71	Antipsychotic drug development. <i>Current Topics in Behavioral Neurosciences</i> , 2010 , 4, 123-39	3.2	18
70	A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial. <i>Journal of Clinical Psychopharmacology</i> , 2010 , 30, 425-30	1.6	20
69	Enhancing outcomes from major depression: using antidepressant combination therapies with multifunctional pharmacologic mechanisms from the initiation of treatment. <i>CNS Spectrums</i> , 2010 , 15, 79-94	1.7	26
68	Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 616-26	4.4	136
67	Applying the principles of adult learning to the teaching of psychopharmacology: overview and finding the focus. <i>CNS Spectrums</i> , 2009 , 14, 179-82	1.7	5
66	Applying the principles of adult learning to the teaching of psychopharmacology: storyboarding a presentation and the rule of small multiples. <i>CNS Spectrums</i> , 2009 , 14, 288-94	1.7	2
65	Crisis in army psychopharmacology and mental health care at Fort Hood. <i>CNS Spectrums</i> , 2009 , 14, 677-84	1.7	5
64	Fibromyalgia--pathways and neurotransmitters. <i>Human Psychopharmacology</i> , 2009 , 24 Suppl 1, S11-7	2.2	35
63	Why psychiatrists should not ignore pain in their patients--focus on fibromyalgia?. <i>Human Psychopharmacology</i> , 2009 , 24 Suppl 1, S1-2	2.2	1
62	Building a better antipsychotic: receptor targets for the treatment of multiple symptom dimensions of schizophrenia. <i>Neurotherapeutics</i> , 2009 , 6, 78-85	6.1	66
61	Multifunctional drugs: a novel concept for psychopharmacology. <i>CNS Spectrums</i> , 2009 , 14, 71-3	1.7	43
60	Mechanism of action of trazodone: a multifunctional drug. <i>CNS Spectrums</i> , 2009 , 14, 536-46	1.7	205
59	Applying the principles of adult learning to the teaching of psychopharmacology: audience response systems. <i>CNS Spectrums</i> , 2009 , 14, 412-4	1.7	2
58	Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants. <i>CNS Spectrums</i> , 2008 , 13, 855-70	1.7	94
57	Selective histamine H1 antagonism: novel hypnotic and pharmacologic actions challenge classical notions of antihistamines. <i>CNS Spectrums</i> , 2008 , 13, 1027-38	1.7	123
56	Personalized medicine, pharmacogenomics, and the practice of psychiatry: on the threshold of predictive therapeutics in psychopharmacology?. <i>CNS Spectrums</i> , 2008 , 13, 115-8	1.7	13
55	Do dopamine partial agonists have partial efficacy as antipsychotics?. <i>CNS Spectrums</i> , 2008 , 13, 279-82	1.7	15
54	The potential role of a corticotropin-releasing factor receptor-1 antagonist in psychiatric disorders. <i>CNS Spectrums</i> , 2008 , 13, 467-83	1.7	17

53	Novel therapeutics for depression: L-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. <i>CNS Spectrums</i> , 2007 , 12, 739-44	1.7	53
52	Overview of trends in modern psychopharmacology. <i>CNS Spectrums</i> , 2007 , 12, 103-5	1.7	1
51	Beyond the dopamine hypothesis to the NMDA glutamate receptor hypofunction hypothesis of schizophrenia. <i>CNS Spectrums</i> , 2007 , 12, 265-8	1.7	64
50	Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. <i>CNS Spectrums</i> , 2007 , 12, 703-11	1.7	17
49	The genetics of schizophrenia converge upon the NMDA glutamate receptor. <i>CNS Spectrums</i> , 2007 , 12, 583-8	1.7	11
48	Novel therapeutics for schizophrenia: targeting glycine modulation of NMDA glutamate receptors. <i>CNS Spectrums</i> , 2007 , 12, 423-7	1.7	19
47	Novel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism. <i>International Journal of Neuropsychopharmacology</i> , 2007 , 10, 575-8	5.5	20
46	Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder. <i>Current Medical Research and Opinion</i> , 2007 , 23, 2815-22	2.4	29
45	Finding what you are not looking for: strategies for developing novel treatments in psychiatry. <i>NeuroRx</i> , 2006 , 3, 3-9		15
44	High-cost use of second-generation antipsychotics under California's Medicaid program. <i>Psychiatric Services</i> , 2006 , 57, 127-9	3.1	45
43	SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. <i>CNS Spectrums</i> , 2005 , 10, 732-47	1.7	349
42	Antidepressant treatment of psychotic major depression: potential role of the sigma receptor. <i>CNS Spectrums</i> , 2005 , 10, 319-23	1.7	46
41	Examination of nighttime sleep-related problems during double-blind, placebo-controlled trials of galantamine in patients with Alzheimer's disease. <i>Current Medical Research and Opinion</i> , 2004 , 20, 517-24	2.4	30
40	Selectivity of SSRIs: individualising patient care through rational treatment choices. <i>International Journal of Psychiatry in Clinical Practice</i> , 2004 , 8 Suppl 1, 3-10	2.3	12
39	Understanding pain in depression. <i>Human Psychopharmacology</i> , 2004 , 19 Suppl 1, S9-S13	2.2	72
38	Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?. <i>International Journal of Neuropsychopharmacology</i> , 2004 , 7, 113-6	5.5	23
37	Atypical antipsychotics: matching receptor profile to individual patient's clinical profile. <i>CNS Spectrums</i> , 2004 , 9, 6-14	1.7	65
36	A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2004 , 6, 159-166		282

35	Antidepressants and somatic symptoms: therapeutic actions are expanding beyond affective spectrum disorders to functional somatic syndromes. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 745-6	4.4	12
34	Differences in mechanism of action between current and future antidepressants. <i>Journal of Clinical Psychiatry</i> , 2003 , 64 Suppl 13, 13-7	4.4	13
33	The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. <i>Journal of Clinical Psychiatry</i> , 2003 , 64 Suppl 19, 6-12	4.4	35
32	At long last, long-lasting psychiatric medications: an overview of controlled-release technologies. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 355-6	4.4	4
31	Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 1322-7	4.4	102
30	Effects of reboxetine on anxiety, agitation, and insomnia: results of a pooled evaluation of randomized clinical trials. <i>Journal of Clinical Psychopharmacology</i> , 2002 , 22, 388-92	1.6	24
29	The psychopharmacology of energy and fatigue. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 7-8	4.4	104
28	Antipsychotic polypharmacy: squandering precious resources?. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 93-4	4.4	40
27	Does depression hurt?. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 273-4	4.4	59
26	Mirror, mirror on the wall, which enantiomer is fairest of them all?. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 656-7	4.4	4
25	Does evidence from clinical trials in psychopharmacology apply in clinical practice?. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 6-7	4.4	40
24	The psychopharmacology of sex, Part 1: Neurotransmitters and the 3 phases of the human sexual response. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 80-1	4.4	24
23	Fibromyalgia: the enigma and the stigma. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 501-2	4.4	3
22	Gut feelings about irritable bowel syndrome. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 590-1	4.4	7
21	Antipsychotic polypharmacy, Part 1: Therapeutic option or dirty little secret?. <i>Journal of Clinical Psychiatry</i> , 1999 , 60, 425-6	4.4	88
20	Antipsychotic polypharmacy, part 2: tips on use and misuse. <i>Journal of Clinical Psychiatry</i> , 1999 , 60, 506-7	4.4	23
19	Sleep electroencephalographic response to muscarinic and serotonin1A receptor probes in patients with major depression and in normal controls. <i>Biological Psychiatry</i> , 1998 , 44, 21-33	1.9	16
18	Effectiveness of ipsapirone, a 5-HT-1A partial agonist, in major depressive disorder: support for the role of 5-HT-1A receptors in the mechanism of action of serotonergic antidepressants. <i>International Journal of Neuropsychopharmacology</i> , 1998 , 1, 11-18	5.5	27

17	Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. <i>Journal of Affective Disorders</i> , 1998 , 51, 215-35	6.3	355
16	Using secondary binding properties to select a not so selective serotonin reuptake inhibitor. <i>Journal of Clinical Psychiatry</i> , 1998 , 59, 642-3	4.4	17
15	Mirtazapine: An Antidepressant with Noradrenergic and Specific Serotonergic Effects. <i>Pharmacotherapy</i> , 1997 , 17, 10-21	5.5	82
14	Nefazodone and the serotonin receptor modulators: a new member of a unique class of antidepressant agents. <i>International Review of Psychiatry</i> , 1995 , 7, 29-39	3.4	4
13	Biochemical pharmacology of serotonin receptor subtypes: hypotheses for clinical applications of selective serotonin ligands. <i>International Review of Psychiatry</i> , 1995 , 7, 55-67	3.4	6
12	Targeting serotonin receptor subtypes as a strategy for the discovery of novel treatments in psychiatry. <i>International Review of Psychiatry</i> , 1995 , 7, 3-4	3.4	
11	Pharmacology: policy implications of new psychiatric drugs. <i>Health Affairs</i> , 1992 , 11, 157-63	0	0
10	Progressive myelopathy due to extramedullary hematopoiesis: case report and review of the literature. <i>Annals of Neurology</i> , 1979 , 5, 485-9	9.1	17
9	Evidence-based pharmacotherapy of major depressive disorder53-72		
8	Evidence-based pharmacotherapy of panic disorder73-89		
7	Molecular and Cellular Biology Research in Psychiatry29-58		
6	Amoxapine		
5	Lemborexant		
4	Agomelatine		
3	Memantine		
2	Brexpiprazole		
1	Lisdexamfetamine		